Evidence map›Paper›PMID 31281490›Full record

ArticleTheranostics2019

RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.

Yang Bai, Yinhui Yang, Yuqian Yan, Jian Zhong, Alexandra M Blee, Yunqian Pan, Tao Ma, R Jeffrey Karnes, Rafael Jimenez, Wanhai Xu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Runt-related transcription factors in human carcinogenesis: a friend or foe?Journal of cancer research and clinical oncology · 2023
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yang BaiHeilongjiang Key Laboratory of Scientific Research in Urology and Department of Urology, the Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang Province, 150081, China.
Yinhui YangHeilongjiang Key Laboratory of Scientific Research in Urology and Department of Urology, the Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang Province, 150081, China.
Yuqian YanDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
Jian ZhongDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
Alexandra M BleeDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
Yunqian PanDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
Tao MaDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
R Jeffrey KarnesDepartment of Urology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
Rafael JimenezDepartment of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
Wanhai XuHeilongjiang Key Laboratory of Scientific Research in Urology and Department of Urology, the Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang Province, 150081, China.
Haojie HuangDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
Mayo Clinic · USWinnMed · US

Funding

Role of proinflammatory cytokine-induced AR degradation in castration-resistant prostate cancerR01CA130908 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI HUANG, HAOJIE · 2010 to 2021
$3.5M
Role of FOXO1 Inactivation in Prostate TumorigenesisR01CA134514 · NCI · UNIVERSITY OF MINNESOTA · PI HUANG, HAOJIE · 2009 to 2019
$3.3M
Role of RUNX2 in prostate cancer intratumoral androgen synthesis and progressionR01CA193239 · NCI · MAYO CLINIC ROCHESTER · PI HUANG, HAOJIE · 2015 to 2019
$1.8M
Mechanism and role of aberrant AR activity in castration-resistant prostate cancerR01CA203849 · NCI · MAYO CLINIC ROCHESTER · PI HUANG, HAOJIE · 2018 to 2022
$1.8M
NCI NIH HHS R01 CA130908NCI NIH HHS R01 CA134514NCI NIH HHS R01 CA193239NCI NIH HHS R01 CA203849
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic NeoplasmsAnimalsCarcinogenesisCell Line, TumorCell Transformation, NeoplasticCore Binding Factor Alpha 1 SubunitGene ExpressionHaploinsufficiencyHumansMaleMiceProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseReceptors, CXCRSignal TransductionACKR3 protein, humanCore Binding Factor Alpha 1 SubunitProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanReceptors, CXCRRUNX2 protein, humanCXCR7prostate cancerPTENRUNX2tumorigenesis

Identifiers

PMID31281490
PMCPMC6587168
OpenAlexW2947683799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.